5,471 Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX) Acquired by Plato Investment Management Ltd

Plato Investment Management Ltd purchased a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 5,471 shares of the company’s stock, valued at approximately $43,000.

Other large investors have also recently bought and sold shares of the company. Beacon Capital Management LLC acquired a new position in GoodRx during the 1st quarter worth approximately $28,000. Gerber LLC acquired a new position in GoodRx during the 4th quarter worth approximately $75,000. Innealta Capital LLC acquired a new position in GoodRx during the 4th quarter worth approximately $91,000. Schnieders Capital Management LLC acquired a new position in GoodRx during the 1st quarter worth approximately $93,000. Finally, EntryPoint Capital LLC boosted its position in GoodRx by 165.2% during the 1st quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock worth $132,000 after acquiring an additional 11,548 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Down 0.9 %

GDRX stock opened at $7.68 on Tuesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.32 and a quick ratio of 7.32. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of -768.00, a PEG ratio of 3.55 and a beta of 1.38. The business’s fifty day moving average price is $8.02 and its two-hundred day moving average price is $7.61. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $200.60 million for the quarter, compared to the consensus estimate of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.02 EPS. On average, equities analysts anticipate that GoodRx Holdings, Inc. will post 0.15 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.17% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on GDRX shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. UBS Group cut their price objective on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Morgan Stanley increased their price objective on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a report on Monday, June 10th. Barclays increased their price objective on GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a report on Monday, May 20th. Finally, Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, GoodRx currently has an average rating of “Moderate Buy” and a consensus target price of $9.36.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.